Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients

R. F. Wolf, D. B. Pearlstone, E. Newman, M. J. Heslin, A. Gonenne, M. E. Burt, M. F. Brennan, David Herndon, D. W. Wilmore, S. Lowry, W. S. Blakemore

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The authors examined the effect of recombinant-human growth hormone (r- hGH) and insulin (INS) administration on protein kinetics in cancer patients. Twenty-eight cancer patients either received r-hGH for 3 days (GH group, n = 12, weight loss = 6 ± 2%) or were not treated (control [CTL] group, n = 16, weight loss = 11 ± 2%) before metabolic study. Recombinant-human growth hormone dose was 0.1 mg/kg/day (n = 6) or 0.2 mg/kg/day (n = 6). Patients then underwent measurement of baseline protein kinetics (GH/B, CTL/B) followed by a 2-hour euglycemic insulin infusion (1 mU/kg/minute) and repeat kinetic measurements (GH/INS,CTL/INS). Whole-body protein net balance (μmol leucine/kg/minute) was higher (p < 0.05) in GH/INS (0.20 ± 0.06) than in CTL/INS (0.06 ± 0.03) or GH/B (-0.19 ± 0.03). Skeletal muscle protein net balance (nmol phenylalanine/100 g/minute) in GH/INS (25 ± 6) and CTL/INS (19 ± 5) was higher than CTL/B (-18 ± 3). Recombinant-human growth hormone and insulin reduce whole-body and skeletal muscle protein loss in cancer patients. Simultaneous use of these agents during nutritional therapy may benefit the cancer patient.

Original languageEnglish (US)
Pages (from-to)280-290
Number of pages11
JournalAnnals of Surgery
Volume216
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Muscle Proteins
Growth Hormone
Skeletal Muscle
Insulin
Neoplasms
Human Growth Hormone
Weight Loss
Proteins
Phenylalanine
Leucine
Control Groups

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Wolf, R. F., Pearlstone, D. B., Newman, E., Heslin, M. J., Gonenne, A., Burt, M. E., ... Blakemore, W. S. (1992). Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Annals of Surgery, 216(3), 280-290.

Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. / Wolf, R. F.; Pearlstone, D. B.; Newman, E.; Heslin, M. J.; Gonenne, A.; Burt, M. E.; Brennan, M. F.; Herndon, David; Wilmore, D. W.; Lowry, S.; Blakemore, W. S.

In: Annals of Surgery, Vol. 216, No. 3, 1992, p. 280-290.

Research output: Contribution to journalArticle

Wolf, RF, Pearlstone, DB, Newman, E, Heslin, MJ, Gonenne, A, Burt, ME, Brennan, MF, Herndon, D, Wilmore, DW, Lowry, S & Blakemore, WS 1992, 'Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients', Annals of Surgery, vol. 216, no. 3, pp. 280-290.
Wolf RF, Pearlstone DB, Newman E, Heslin MJ, Gonenne A, Burt ME et al. Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. Annals of Surgery. 1992;216(3):280-290.
Wolf, R. F. ; Pearlstone, D. B. ; Newman, E. ; Heslin, M. J. ; Gonenne, A. ; Burt, M. E. ; Brennan, M. F. ; Herndon, David ; Wilmore, D. W. ; Lowry, S. ; Blakemore, W. S. / Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients. In: Annals of Surgery. 1992 ; Vol. 216, No. 3. pp. 280-290.
@article{e6338f73a5da4011a269fe9b3ff7dffe,
title = "Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients",
abstract = "The authors examined the effect of recombinant-human growth hormone (r- hGH) and insulin (INS) administration on protein kinetics in cancer patients. Twenty-eight cancer patients either received r-hGH for 3 days (GH group, n = 12, weight loss = 6 ± 2{\%}) or were not treated (control [CTL] group, n = 16, weight loss = 11 ± 2{\%}) before metabolic study. Recombinant-human growth hormone dose was 0.1 mg/kg/day (n = 6) or 0.2 mg/kg/day (n = 6). Patients then underwent measurement of baseline protein kinetics (GH/B, CTL/B) followed by a 2-hour euglycemic insulin infusion (1 mU/kg/minute) and repeat kinetic measurements (GH/INS,CTL/INS). Whole-body protein net balance (μmol leucine/kg/minute) was higher (p < 0.05) in GH/INS (0.20 ± 0.06) than in CTL/INS (0.06 ± 0.03) or GH/B (-0.19 ± 0.03). Skeletal muscle protein net balance (nmol phenylalanine/100 g/minute) in GH/INS (25 ± 6) and CTL/INS (19 ± 5) was higher than CTL/B (-18 ± 3). Recombinant-human growth hormone and insulin reduce whole-body and skeletal muscle protein loss in cancer patients. Simultaneous use of these agents during nutritional therapy may benefit the cancer patient.",
author = "Wolf, {R. F.} and Pearlstone, {D. B.} and E. Newman and Heslin, {M. J.} and A. Gonenne and Burt, {M. E.} and Brennan, {M. F.} and David Herndon and Wilmore, {D. W.} and S. Lowry and Blakemore, {W. S.}",
year = "1992",
language = "English (US)",
volume = "216",
pages = "280--290",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients

AU - Wolf, R. F.

AU - Pearlstone, D. B.

AU - Newman, E.

AU - Heslin, M. J.

AU - Gonenne, A.

AU - Burt, M. E.

AU - Brennan, M. F.

AU - Herndon, David

AU - Wilmore, D. W.

AU - Lowry, S.

AU - Blakemore, W. S.

PY - 1992

Y1 - 1992

N2 - The authors examined the effect of recombinant-human growth hormone (r- hGH) and insulin (INS) administration on protein kinetics in cancer patients. Twenty-eight cancer patients either received r-hGH for 3 days (GH group, n = 12, weight loss = 6 ± 2%) or were not treated (control [CTL] group, n = 16, weight loss = 11 ± 2%) before metabolic study. Recombinant-human growth hormone dose was 0.1 mg/kg/day (n = 6) or 0.2 mg/kg/day (n = 6). Patients then underwent measurement of baseline protein kinetics (GH/B, CTL/B) followed by a 2-hour euglycemic insulin infusion (1 mU/kg/minute) and repeat kinetic measurements (GH/INS,CTL/INS). Whole-body protein net balance (μmol leucine/kg/minute) was higher (p < 0.05) in GH/INS (0.20 ± 0.06) than in CTL/INS (0.06 ± 0.03) or GH/B (-0.19 ± 0.03). Skeletal muscle protein net balance (nmol phenylalanine/100 g/minute) in GH/INS (25 ± 6) and CTL/INS (19 ± 5) was higher than CTL/B (-18 ± 3). Recombinant-human growth hormone and insulin reduce whole-body and skeletal muscle protein loss in cancer patients. Simultaneous use of these agents during nutritional therapy may benefit the cancer patient.

AB - The authors examined the effect of recombinant-human growth hormone (r- hGH) and insulin (INS) administration on protein kinetics in cancer patients. Twenty-eight cancer patients either received r-hGH for 3 days (GH group, n = 12, weight loss = 6 ± 2%) or were not treated (control [CTL] group, n = 16, weight loss = 11 ± 2%) before metabolic study. Recombinant-human growth hormone dose was 0.1 mg/kg/day (n = 6) or 0.2 mg/kg/day (n = 6). Patients then underwent measurement of baseline protein kinetics (GH/B, CTL/B) followed by a 2-hour euglycemic insulin infusion (1 mU/kg/minute) and repeat kinetic measurements (GH/INS,CTL/INS). Whole-body protein net balance (μmol leucine/kg/minute) was higher (p < 0.05) in GH/INS (0.20 ± 0.06) than in CTL/INS (0.06 ± 0.03) or GH/B (-0.19 ± 0.03). Skeletal muscle protein net balance (nmol phenylalanine/100 g/minute) in GH/INS (25 ± 6) and CTL/INS (19 ± 5) was higher than CTL/B (-18 ± 3). Recombinant-human growth hormone and insulin reduce whole-body and skeletal muscle protein loss in cancer patients. Simultaneous use of these agents during nutritional therapy may benefit the cancer patient.

UR - http://www.scopus.com/inward/record.url?scp=0026803309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026803309&partnerID=8YFLogxK

M3 - Article

C2 - 1417177

AN - SCOPUS:0026803309

VL - 216

SP - 280

EP - 290

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 3

ER -